DOSING REGIMEN FOR GP100-SPECIFIC TCR - ANTI-CD3 SCFV FUSION PROTEIN

• 收藏
• 分享

专利权人:

IMMUNOCORE LIMITED

发明人:

Christina COUGHLIN

申请号：

US16305838

公开号：

US20200040055A1

申请日:

2017.06.02

申请国别(地区):

US

年份:

2020

代理人:

摘要：

The present invention relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA-HLA-A2 complex fused to a CD3 binding T cell redirecting moiety.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/